期刊文献+

漆黄素对脑胶质瘤体外侵袭的抑制作用及其机制 被引量:3

Effects and mechanism of fisetin to inhibiting invasion of human glioma in vitro
原文传递
导出
摘要 目的:脑胶质瘤是发生率最高的恶性脑肿瘤,因具有高侵袭高浸润性的特点,使其预后效果差,中位生存期只有14.6个月,因此,寻找新的治疗药物或治疗手段意义重大。目前,许多研究发现漆黄素作为一种天然黄酮类化合物具有抗肿瘤作用,对多种肿瘤细胞具有明显抑制作用。然而漆黄素是否作用于脑胶质瘤细胞尚未得到深入探讨。方法:以U-87MG恶性胶质瘤细胞系作为研究对象,利用Transwell侵袭实验和Wound-healing划痕实验检测漆黄素处理后细胞的体外侵袭和迁移能力;利用MTS法检测细胞生长情况,利用流式细胞分析技术检测对漆黄素处理后细胞的细胞周期和细胞凋亡进行分析;利用Western-blot和Real-time PCR技术对相关基因的蛋白和mRNA表达水平进行检测。结果:漆黄素处理后,U-87MG细胞的侵袭力和迁移力显著降低,G2/M期细胞增多,细胞凋亡显著提高,同时相关基因的表达水平也有明显变化。结论:这些实验结果暗示漆黄素可通过调节细胞周期、促进细胞凋亡而明显降低脑胶质瘤细胞的侵袭和迁移力,从而对脑胶质瘤细胞具有显著的抗肿瘤作用。 OBJECTIVE Glioblastoma is the most frequent malignant form of brain cancer.For its high rate of invasion and migration,its median survival time is only 14.6 months.So it is essential to find out new therapeutic options.Fisetin,a naturally occurring flavonoid,has been shown to exert obviously anti-cancer effects against many types of tumor.However,whether fisetin can inhibit tumorigenesis of glioblastoma cells has not been fully researched.METHODS Effects of fisetin against invasion,migration,proliferation,cell cycle and apoptosis of U-87 MG treated with fisetin were detected via Transwell,Woundhealing,MTS,and flow cytometric analysis,respectively.Protein levels and mRNA expression levels of related genes were detected by Western-blot and Real-time-PCR assays,respectively.RESULTS Invasion and migration of U-87 MG were obviously inhibited,cell cycle progression was dramatically blocked in G2/M phase,and apoptosis also significantly increased.CONCLUSION These results strongly suggest that fisetin may exert its anti-tumor effects to glioblastoma by suppressing invasion and migration via inducing cell cycle arrest in G2/M phase and inducing cell apoptosis.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第13期1051-1055,共5页 Chinese Journal of Hospital Pharmacy
基金 天津市卫生局科技基金项目(编号:2012KZ033)
关键词 脑胶质瘤 漆黄素 转移 细胞周期 细胞凋亡 glioblastoma fisetin migration cell-cycle apoptosis
  • 相关文献

参考文献15

  • 1王华,刘艳飞.吉西他滨诱导神经胶质瘤细胞凋亡及其对促凋亡因子Bax/Bak的影响[J].中国医院药学杂志,2015,35(23):2092-2096. 被引量:4
  • 2Schroder LB, Mcdonald KL. CDK4/6 inhibitor PD0332991 inglioblastoma treatment: does it have a future? [J]. Front On-col, 2015,5: 259.
  • 3Rutledge MR, Waddell JA,Solimando DA. Bevacizumab andtemozolomide plus radiation regimen for glioblastoma multi-forme[J], Hosp Pharm, 2015,50(8) : 672-677.
  • 4Seo SH, Jeong GS, Fisetin inhibits TNF-a-induced inflamma-tory action and Hydrogen peroxide-induced oxidative damage inhuman keratinocyte HaCaT cells through PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression [J]. Int Immunop-harmacol, 2015, 29(2): 246-253.
  • 5Zhang JQ, Jiang KM, An K,et aL Novel water-soluble fise-tin/cyclodextrins inclusion complexes: Preparation, character-ization, molecular docking and bioavailability [J]. CarbohydrRes,2015,418: 20-28.
  • 6Je HD, Sohn UD, La HO. Endothelium-Independent effect offisetin on the Agonist-Induced regulation of vascular contractil-Biomol Ther (Seoul)* 2016,24(1): 57-61.
  • 7Huang J, Shi Y, Li H, et al. Knockdown of receptor tyrosinekinase-like orphan receptor 2 inhibits cell proliferation and col-ony formation in osteosarcoma cells by inducing arrest in cellcycle progression[J]. Oncol Lett, 2015,10(6) : 3705-3711.
  • 8曹华,胡廷婷,杨成莉,张利静,贺英菊,郑瑀.结肠癌靶向米托蒽醌脂质体的制备及其抗肿瘤活性研究[J].中国医院药学杂志,2016,36(1):4-9. 被引量:2
  • 9ChouRH,Hsieh SC, Yu Yh^ etal, Fisetin inhibits migrationand invasion of human cervical cancer cells by down-regulatingurokinase plasminogen activator expression through suppress-ing the p38 MAPK-dependent NF-kB signaling pathway [J].PLoS One, 2013,8(8): e71983.
  • 10Salem N, Kamal I,Al-Maghrabi J,et al. High expression ofmatrix metalloproteinases : MMP-2 and MMP-9 predicts poorsurvival outcome in colorectal carcinoma[J]? Future Oncol,2016, 12(3): 323-331.

二级参考文献34

  • 1杨翠霞,高锋.透明质酸与其受体CD44在肿瘤研究中的意义[J].肿瘤,2006,26(2):206-209. 被引量:7
  • 2Stewart LA. Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials[J]. The Lancet, 2002, 359(9311):1011-1018.
  • 3Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma:genetics, biology, and paths to treatment[J]. Genes & development, 2007, 21(21):2683-2710.
  • 4Marumoto T, Saya H. Molecular biology of glioma[M]//Glioma. Springer New York, 2012:2-11.
  • 5Sai K, Yang QY, Shen D, et al. Chemotherapy for gliomas in China's Mainland:an overview[J]. Oncology letters, 2013, 5(5):1448-1452.
  • 6Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy[J]. Nature, 2012, 488(7412):522-526.
  • 7Galbán S, Lemasson B, Williams TM, et al. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma[J]. PloS one, 2012, 7(4):e35857.
  • 8Liu S, Guo Y, Huang R, et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma[J]. Biomaterials, 2012, 33(19):4907-4916.
  • 9Vera M, Barcia E, Negro S, et al. New celecoxib multiparticulate systems to improve glioblastoma treatment[J]. International journal of pharmaceutics, 2014, 473(1):518-527.
  • 10Galb n S, Lemasson B, Williams TM, et al. Gemcitabine is evaluated as an alternative treatment to temozolomide for high grade gliomas[J]. Cancer Research, 2011, 71(8 Supplement):5281.

共引文献4

同被引文献27

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部